The role of Helicobacter pylori infection in functional dyspepsia remains controversial. Several randomized controlled trials in western countries have shown no significant advantage over placebo. But some recent studies in Asian population were different compared to the result of studies in the Western population. At the present time, it seems to be difficult to conclude the efficacy of the H.pylori eradication therapy in patients with H. pylori-infected functional dyspepsia. The investigators hypothesize that eradication of Helicobacter pylori has a sustained global symptom improvement in patients with H. pylori infected functional dyspepsia.
Functional dyspepsia: diagnosed by Rome III criteria of Functional gastrointestinal disorder Treatment regimen: Combination of proton pump inhibitor, Amoxicillin, Clarithromycin for 7 days Placebo: Same shaped placebo drugs
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
400
Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
Korean Society of Helicobacter and Upper GI Research
Seoul, Seoul, South Korea
Global symptom improvement after eradication of Helicobacter pylori in patients with functional dyspepsia therapy)
Time frame: Symptom assessment at 8 weeks after eradication
To improves the quality of life
Time frame: 1 year
Global symptom improvement, at 4 weeks after Helicobacter pylori eradication therapy
Time frame: 1 year
The improvement of 8 dyspeptic symptom
Time frame: 1 year
The adequate relief of symptom
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.